Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(1):10-8
Article Links
Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing
Dirk Roggenbuck1,2, Emilien Delmont3, Dirk Reinhold4, Peter Schierack1,2, Karsten Conrad5, Joseph Boucraut6,7
Authors Information
1. Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology  Cottbus – Senftenberg, the Brandenburg Medical School Theodor Fontane and the  University of Potsdam, Germany
2. Institute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg University of Technology Cottbus Senftenberg, Senftenberg, Germany
3. Referral Center for Neuromuscular Diseases and ALS, La Timone Hospital, AP-HM, Marseille, France
4. Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
5. Institute of Immunology, Medical Faculty of the Technical University Dresden, Dresden, Germany
6. Aix Marseille Université, Institut de Neurosciences de la Timone, Medicine Faculty, Marseille, France
7. Immunology laboratory, Conception Hospital, AP-HM, Marseille, France
Keywords: immune-mediated polyneuropathy, ganglioside, sulphatide, autoantibody
References
  1. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125(Pt 12):2591-625.
  2. Roggenbuck JJ, Boucraut J, Delmont E, Conrad K, Roggenbuck D. Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies. Ann Transl Med 2018 2018 Sep;6(17):337.
  3. Willison HJ. Anti-ganglioside Antibodies in Peripheral Nerve Pathology. Methods Mol Biol 2018;1804:173-88.
  4. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178(5):1771-5.
  5. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007;35(6):691-711.
  6. Groux-Degroote S, Guerardel Y, Delannoy P. Gangliosides: Structures, Biosynthesis, Analysis, and Roles in Cancer. Chembiochem 2017;18(13):1146-54.
  7. Klenk E. Über die Ganglioside des Gehirns bei der infantilen amaurotischen Idiotie vom Typ Tay-Sachs. Berichte der deutschen chemischen Gesellschaft 1942;75:1632.
  8. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99(16):10231-3.
  9. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387(6633):569-72.
  10. Kanda T. Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry 2013;84(2):208-12.
  11. Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Lekman A, Månsson JE, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994;1214(2):115-23.
  12. Kolter T. Ganglioside biochemistry. ISRN Biochem 2012;2012:506160.
  13. Xiao S, Finkielstein CV, Capelluto DG. The enigmatic role of sulfatides: new insights into cellular functions and mechanisms of protein recognition. Adv Exp Med Biol 2013;991:27-40.
  14. Honke K. Biosynthesis and biological function of sulfoglycolipids. Proc Jpn Acad Ser B Phys Biol Sci 2013;89(4):129-38.
  15. Ishibashi T, Dupree JL, Ikenaka K, Hirahara Y, Honke K, Peles E, et al. A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J Neurosci 2002;22(15):6507-14.
  16. Saida T, Saida K, Dorfman SH, Silberberg DH, Sumner AJ, Manning MC, et al. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979;204(4397):1103-6.
  17. Ledeen RW, Yu RK, Eng LF. Gangliosides of human myelin: sialosylgalactosylceramide (G7) as a major component. J Neurochem 1973;21(4):829-39.
  18. Ilyas AA, Willison HJ, Quarles RH,  Jungalwala FB, Cornblath DR, Trapp BD, et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 1988;23(5):440-7.
  19. Ilyas AA, Quarles RH, MacIntosh TD, Dobersen MJ, Trapp BD, Dalakas MC, et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci U S A 1984;81(4):1225-9.
  20. Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999;122(Pt 3):449-60.
  21. Rasband MN. Composition, assembly, and maintenance of excitable membrane domains in myelinated axons. Semin Cell Dev Biol 2011;22(2):178-84.
  22. Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 2010;75(22):1961-7.
  23. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27(15):3956-67.
  24. Willison HJ, Paterson G, Kennedy PG, Veitch J. Cloning of human anti-GM1 antibodies from motor neuropathy patients. Ann Neurol 1994;35(4):471-8.
  25. Goodfellow JA, Willison HJ. Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Curr Opin Neurol 2016;29(5):572-80.
  26. Townson K, Boffey J, Nicholl D, Veitch J, Bundle D, Zhang P, et al. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology 2007;17(3):294-303.
  27. Willison HJ, O'Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124(Pt 10):1968-77.
  28. Querol L, Siles AM, Alba-Rovira R, Jáuregui A, Devaux J, Faivre-Sarrailh C, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep 2017;7(1):14411.
  29. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47(6):765-75.
  30. Meyer zu HG, Hartung HP, Kieseier BC. From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3(4):198-211.
  31. Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015;86(9):973-85.
  32. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 2013;124(10):1928-34.
  33. Uncini A, Yuki N. Sensory Guillain-Barre syndrome and related disorders: an attempt at systematization. Muscle Nerve 2012;45(4):464-70.
  34. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980;37(10):637-40.
  35. Quast I, Keller CW, Hiepe F, Tackenberg B, Lünemann JD. Terminal complement activation is increased and associated with disease severity in CIDP. Ann Clin Transl Neurol 2016;3(9):730-5
  36. Schneider-Hohendorf T, Schwab N, Uceyler N, Göbel K, Sommer C, Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012;78(6):402-8.
  37. Klehmet J, Goehler J, Ulm L, Kohler S, Meisel C, Meisel A, et al. Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP. J Neurol Neurosurg Psychiatry 2015;86(6):686-91.
  38. Yang M, Peyret C, Shi XQ, Siron N, Jang JH, Wu S, et al. Evidence from Human and Animal Studies: Pathological Roles of CD8(+) T Cells in Autoimmune Peripheral Neuropathies. Front Immunol 2015;6:532.
  39. Mori L, De LG. T cells specific for lipid antigens. Immunol Res 2012;53(1-3):191-9.
  40. Gras S, Van R, I, Shahine A, Le Nours J. Molecular recognition of microbial lipid-based antigens by T cells. Cell Mol Life Sci 2018;75(9):1623-39.
  41. Le NJ, Shahine A, Gras S. Molecular features of lipid-based antigen presentation by group 1 CD1 molecules. Semin Cell Dev Biol 2018;84:48-57.
  42. Zhang T, de Waard AA, Wuhrer M, Spaapen RM. The Role of Glycosphingolipids in Immune Cell Functions. Front Immunol 2019;10:90.
  43. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745(1-2):32-6.
  44. Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O'Leary C, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009;119(3):595-610.
  45. Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain-Barre syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82(3):294-9.
  46. Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J, et al. Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest 2012;122(3):1037-51.
  47. Conrad K, Schneider H, Ziemssen T, Talaska T, Reinhold D, Humbel RL, et al. A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. Ann N Y Acad Sci 2007;1109:256-64.
  48. Townson K, Greenshields KN, Veitch J, Nicholl D, Eckhardt M, Galanina O, et al. Sulfatide binding properties of murine and human antiganglioside antibodies. Glycobiology 2007;17(11):1156-66.
  49. Attarian S, Boucraut J, Hubert AM, Uzenot D, Delmont E, Verschueren A, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry 2010;81(1):61-4.
  50. Delmont E, Jeandel PY, Hubert AM, Marcq L, Boucraut J, Desnuelle C. Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol 2010;257(4):655-7.
  51. Rinaldi S, Brennan KM, Kalna G, Walgaard C, van Doorn P, Jacobs BC, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barre syndrome. PLoS One 2013;8(12):e82337.
  52. Palavicini JP, Wang C, Chen L, Ahmar S, Higuera JD, Dupree JL, et al. Novel molecular insights into the critical role of sulfatide in myelin maintenance/function. J Neurochem 2016;139(1):40-54.
  53. Dabby R, Weimer LH, Hays AP, Olarte M, Latov N. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 2000;54(7):1448-52.
  54. Lopate G, Kornberg AJ, Yue J, et al. Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve. J Neurol Sci 2001;188(1-2):67-72.
  55. Giannotta C, Di PD, Gallia F, Choksi R, Pestronk A. Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test? Eur J Neurol 2015;22(5):879-82.
  56. Campagnolo M, Ferrari S, Dalla TC, Cabrini I, Cacciavillani M, Lucchetta M, et al. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol 2015;281:1-4.
  57. Fraussen J, Claes N, de BL, Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 2014;13(11):1126-37.
  58. Burger D, Simon M, Perruisseau G, Steck AJ. The epitope(s) recognized by HNK-1 antibody and IgM paraprotein in neuropathy is present on several N-linked oligosaccharide structures on human P0 and myelin-associated glycoprotein. J Neurochem 1990;54(5):1569-75.
  59. Nobile-Orazio E, Giannotta C, Musset L, Messina P, Léger JM. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2014;85(7):754-8.
  60. Nobile-Orazio E, Giannotta C, Briani C. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol 2010;219(1-2):119-22.
  61. Willison HJ, Jacobs BC, Van Doorn PA. Guillain-Barre syndrome. Lancet 2016;388(10045):717-27.
  62. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31(6):677-9.
  63. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999;45(2):189-99.
  64. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255(2):57-65.
  65. Yuki N, Susuki K, Hirata K. Ataxic Guillain-Barre syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology 2000;54(9):1851-3.
  66. Serrano-Munuera C, Gallardo E, Rojas R, De Luna N, González-Masegosa A, Martí-Massó JF, et al. Antiganglioside antibodies in acute self-limiting ataxic neuropathy: incidence and significance. J Neuroimmunol 2001;120(1-2):78-83.
  67. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody. Neurology 2003;61(4):465-70.
  68. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol 1999;45(2):168-73.
  69. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39(5):625-35.
  70. Yuki N, Susuki K, Hirata K. Ataxic form of Guillain-Barr syndrome associated with anti-GD1b IgG antibody. J Neurol Neurosurg Psychiatry 2000;69(1):136-7.
  71. Ilyas AA, Quarles RH, Dalakas MC, Fishman PH, Brady RO. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985;18(6):655-9.
  72. Obi T, Kusunoki S, Takatsu M, Mizoguchi K, Nishimura Y. IgM M-protein in a patient with sensory-dominant neuropathy binds preferentially to polysialogangliosides. Acta Neurol Scand 1992;86(2):215-8.
  73. Chabraoui F, Derrington EA, Mallie-Didier F, Confavreux C, Quincy C, Caudie C. Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. J Immunol Methods 1993;165(2):225-30.
  74. Alaedini A, Latov N. Detection of anti-GM1 ganglioside antibodies in patients with neuropathy by a novel latex agglutination assay. J Immunoassay 2000;21(4):377-86.
  75. Escande-Beillard N, David MJ, Portoukalian J, Pouget J, Azulay JP, Bernard D, et al. A sensitive flow cytometry method for anti-GM1 antibodies detection. J Neuroimmunol 2002;125(1-2):163-9.
  76. Caudie C. Monoclonal IgM autoantibody reactivity in M-IgM peripheral neuropathy. Clin Rev Allergy Immunol 2000;19(1):7-18.
  77. Caudie C, Vial C, Petiot P, Bouhour F. [Serum antibody profiles against gangliosides and sulfatide in peripheral neuropathies: evaluation of a new immunoassay]. [Article in Frence] Ann Biol Clin (Paris) 2010;68(6):675-80.
  78. Milnik A, Roggenbuck D, Conrad K, Bartels C. Acute inflammatory neuropathy with monoclonal anti-GM2 IgM antibodies, IgM-k paraprotein and additional autoimmune processes in association with a diffuse large b-cell non-Hodgkin’s lymphoma. BMJ Case Rep 2013. pii: bcr1120115087.
  79. Seifert M, Schoenherr G, Roggenbuck D, Marx U, von Baehr R. Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria. Hybridoma 1996;15(3):191-8.
  80. Schoenherr G, Roggenbuck D, Seifert M, Jahn S, Porstmann T. Technical problems arising from the use of the immunoblot for determination of the reactivity of natural antibodies with different lipopolysaccharides (LPS). J Immunol Methods 1996;190(2):185-8.
  81. Roggenbuck D, Borghi MO, Somma V, Büttner T, Schierack P, Hanack K, et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther 2016;18(1):111.
  82. Roggenbuck D, Somma V, Schierack P, Borghi MO, Meroni PL. Autoantibody profiling in APS. Lupus 2014;23(12):1262-4
  83. Nalli C, Somma V, Andreoli L, Büttner T, Schierack P, Mahler M, et al. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights 2018;9(1):6.
  84. Roggenbuck D, Egerer K, von Landenberg P, Hiemann R, Feist E, Burmester GR, et al. Antiphospholipid antibody profiling - Time for a new technical approach. Autoimmun Rev 2012;11(11):821-6.
  85. Egerer K, Roggenbuck D, Buettner T, Lehmann B, Kohn A, von Landenberg P, et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther 2011;13(4):R118.
  86. Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999;6(1):71-7.
  87. Caudie C, Quittard PA, Taravel D, Sivadon-Tardy V, Orlikowski D, Rozenberg F, et al. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barre syndrome patients. J Neurol 2011;258(11):1958-64.
  88. Klehmet J, Marschenz S, Ruprecht K, Wunderlich B, Büttner T, Hiemann R, et al. Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab Med 2018.
  89. Morikawa M, Kuwahara M, Ueno R, Samukawa M, Hamada Y, Kusunoki S. Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies. J Neuroimmunol 2016;301:35-40.